Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
TRAE were consistent with tebentafusp's mechanism of action, mostly occurred during dose escalation, and were predictable, reversible, and manageable with appropriate surveillance and intervention.
Authors
- Sophie Piperno‐Neumann (ORCID: https://orcid.org/0000-0001-9915-2810)
- John M. Kirkwood (ORCID: https://orcid.org/0000-0002-3570-4476)
- Marcus O. Butler (ORCID: https://orcid.org/0000-0002-9840-7057)
- Ryan J. Sullivan (ORCID: https://orcid.org/0000-0001-5344-6645)
- Josep M. Piulats (ORCID: https://orcid.org/0000-0002-3606-1724)
- Ramakrishna Edukulla (ORCID: https://orcid.org/0009-0004-7535-9867)
- Jean‐François Baurain (ORCID: https://orcid.org/0000-0003-4876-4600)
- Sebastian Ochsenreither (ORCID: https://orcid.org/0000-0001-6024-4312)
- Alexander Noor Shoushtari (ORCID: https://orcid.org/0000-0002-8065-4412)
- Max Schlaak (ORCID: https://orcid.org/0000-0002-1663-8098)
- Mark R. Middleton (ORCID: https://orcid.org/0000-0003-0167-1685)
- Takami Sato (ORCID: https://orcid.org/0000-0003-2221-0415)
- Jessica Cecile Hassel (ORCID: https://orcid.org/0000-0001-7575-6230)
- Piotr Rutkowski (ORCID: https://orcid.org/0000-0002-8920-5429)
- Joseph J. Sacco (ORCID: https://orcid.org/0000-0003-2591-9796)
- Constance Pfeiffer (ORCID: https://orcid.org/0009-0006-4290-0519)
- Anthony M. Joshua (ORCID: https://orcid.org/0000-0001-5159-4580)
- Paul Nathan (ORCID: https://orcid.org/0000-0002-2327-3250)
- Richard D. Carvajal (ORCID: https://orcid.org/0000-0002-3796-1118)
- Reinhard Dummer (ORCID: https://orcid.org/0000-0002-2279-6906)
- Alexandra P. Ikeguchi (ORCID: https://orcid.org/0000-0002-4448-9755)
Institutions
- Northwell Health (US)
- Cliniques Universitaires Saint-Luc (BE)
- University Health Network (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Institut Català d'Ornitologia (ES)
- The University of Texas MD Anderson Cancer Center (US)
- University of Liverpool (GB)
- University of Toronto (CA)
- Heidelberg University (DE)
- Université Paris Sciences et Lettres (FR)
- University Hospital Heidelberg (DE)
- Princess Margaret Cancer Centre (CA)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- Humboldt-Universität zu Berlin (DE)
- Kettering University (US)
- University of Oxford (GB)
- St Vincent's Hospital Sydney (AU)
- Massachusetts General Hospital (US)
- Immunocore (United States) (US)
- University Hospital of Zurich (CH)
- Immunocore (United Kingdom) (GB)
- Sidney Kimmel Cancer Center (US)
- Institut Català d'Oncologia (ES)
- Mount Vernon Cancer Centre (GB)
- Oxford MicroMedical (United Kingdom) (GB)
- National Center for Tumor Diseases (DE)
- Macula Vision Research Foundation (US)
- University of Pittsburgh Medical Center (US)
- Science Oxford (GB)
- Center for Cancer Research (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- The Kinghorn Cancer Centre (AU)
- Merseytravel (GB)
- Amplimmune (United States) (US)
- Kantonsspital Aarau (CH)
- Charité - Universitätsmedizin Berlin (DE)
- Institut Curie (FR)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1513
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Memorial Sloan-Kettering Cancer Center
- National Cancer Institute